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Introduction 
 
The PRL family of phosphatases has gained 
much attention in recent years as potential tar-
gets for therapeutic intervention in a variety of 
tumor types. The family consists of three closely 
related members (PRL-1, PRL-2, and PRL-3), 
which constitute a novel class of protein tyro-
sine phosphatase (PTP). The PRLs are among 
the smallest of the PTPs, having molecular 
masses of 20-22kDa and consisting primarily of 
a catalytic domain. In addition, the PRL en-
zymes are the only PTPs known to be post-
translationally isoprenylated. This post-
translational modification is critical to their sub-
cellular localization and biological activity [1-3].  
Accumulating evidence points to a role for the 
PRL family in tumor formation, invasion, and 
metastasis. Functional studies have shown that 
overexpression of PRL-1, -2, or -3 in non-
tumorigenic rodent cells leads to rapid cellular 
growth and a transformed phenotype in culture 
and to tumor formation in athymic, nude mice 
[1, 4-7]. Moreover, PRL-3 overexpression en-
hances the growth of human embryonic kidney 
fibroblasts in culture [5] and can transform a 
low metastatic potential melanoma cell line into 
a highly metastatic line both in vitro and in vivo 
[6]. Stable expression of PRL-1 or PRL-3 leads 
to enhanced cell motility and invasive ability, 
whereas downregulation of either of these mole-
cules causes a significant reduction in migratory 
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Abstract: The PRL-1 and PRL-2 phosphatases have been implicated as oncogenic, however the involvement of these 
molecules in human neoplasms is not well understood. To increase understanding of the role PRL-1 and PRL-2 play 
in the neoplastic process, in situ hybridization was used to examine PRL-1 and PRL-2 mRNA expression in 285 nor-
mal, benign, and malignant human tissues of diverse origin. Immunohistochemical analysis was performed on a sub-
set of these. PRL-1 and PRL-2 mRNA expression was also assessed in a small set of samples from a variety of dis-
eases other than cancer. Where possible, associations with clinicopathological characteristics were evaluated. Altera-
tions in PRL-1 or -2 expression were a frequent event, but the nature of those alterations was highly tumor type spe-
cific. PRL-1 was significantly overexpressed in 100% of hepatocellular and gastric carcinomas, but significantly under-
expressed in 100% of ovarian, 80% of breast, and 75% of lung tumors. PRL-2 expression was significantly increased 
in 100% of hepatocellular carcinomas, yet significantly downregulated in 54% of kidney carcinomas. PRL-1 expres-
sion was correlated to patient gender in the bladder and to patient age in the brain and skeletal muscle. PRL-1 ex-
pression was also associated with tumor grade in the prostate, ovary, and uterus. These results suggest a pleiotropic 
role for PRL-1 and PRL-2 in the neoplastic process. These molecules may associate with tumor progression and serve 
as clinical markers of tumor aggressiveness in some tissues, but be involved in inhibition of tumor formation or 
growth in others.  
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ability in vitro and suppression of metastatic 
tumor formation in vivo [7-14]. The most well 
studied PRL family member, in relation to hu-
man cancer, is PRL-3. Widespread interest in 
this gene was generated after Saha et al. [15] 
identified 144 gene transcripts with increased 
expression in liver metastases compared to 
their primary colorectal tumors and demon-
strated that PRL-3 was the only gene consis-
tently overexpressed in all 18 of the metastatic 
cases examined. A gradient in PRL-3 expression 
was also noted, with low levels of PRL-3 mes-
sage in normal colorectal epithelium, intermedi-
ate levels in the primary tumors, and high ex-
pression in each of the liver metastases. 
Bardelli et al. [16] later showed that PRL-3 
mRNA overexpression was not limited to liver 
metastases, but that PRL-3 was expressed 
more highly in all colorectal carcinoma metasta-
ses examined, regardless of the site of metasta-
sis. PRL-3 overexpression has since been linked 
to such clinical parameters as disease progres-
sion, tumor aggressiveness, lymphatic invasion, 
venous invasion, presence and extent of metas-
tasis, or poor patient prognosis in colon/
colorectal [17-20], cervical [21], ovarian [22, 
23], breast [24-26], gastric [27-35], non-small 
cell lung [36], esophageal [37], nasopharyngeal 
[12], brain [38], hepatocellular [39] and bile 
duct [40] cancers. These data suggest PRL-3 as 
a potential prognostic indicator of disease ag-
gressiveness and clinical outcome for multiple 
tumor types. 
 
In contrast to PRL-3, little data is currently avail-
able on the expression of PRL-1 or PRL-2 in hu-
man malignancies, yet it is clear from cell line 
and murine studies that these genes also play 
important roles in tumor formation, invasion, 
and metastasis [1, 7, 41-43]. In the current 
study, we provide further insight into the role 
that both PRL-1 and PRL-2 play in the develop-
ment and progression of human disease by per-
forming a retrospective analysis on 342 human 
tissue specimens from 243 individual subjects. 
The expression of PRL-1 and PRL-2 mRNA was 
assessed in a variety of normal and tumor tis-
sues of diverse tissue origin using in situ hy-
bridization. Where possible, correlations be-
tween PRL-1 or -2 mRNA expression and several 
clinicopathological features, including patient 
age and gender, tumor type and grade, and 
presence or absence of local or distant metasta-
ses were investigated. A comparison between 
mRNA and protein expression levels was also 
made in a subset of these tissues. In addition, 
because PRL-3 overexpression in mouse mod-
els has previously been linked to cardiovascular 
disease [5] and PTPs in general have been im-
plicated in the progression of several cardiovas-
cular, neurological, metabolic, and autoimmune 
diseases [44-47], we also examined the rela-
tionship between PRL-1 and PRL-2 expression 
and a variety of disease states other than can-
cer. 
 
Materials and methods 
 
Tissue procurement 
 
Formalin-fixed, paraffin-embedded tissue sam-
ples were obtained from archival paraffin 
blocks. Tissues were acquired from the Coop-
erative Human Tissue Network (CHTN), National 
Disease Research Interchange (NDRI), or Indi-
ana University School of Medicine, Department 
of Pathology, collected in accordance with the 
guidelines of Indiana University and with ap-
proval from the IUPUI Institutional Review 
Board. Tissue sections of each specimen were 
stained with Hematoxylin and Eosin (H&E) and 
were examined by a pathologist, with no prior 
knowledge of the available patient data, to con-
firm histopathologic diagnosis and tumor grad-
ing. For all cases, representative tissue sections 
were chosen for in situ hybridization (ISH) and/
or immunohistochemical (IHC) analysis. 
 
In situ hybridization 
 
Non-isotopic ISH was performed using FITC-
labeled oligonucleotide probes specific for PRL-
1 or PRL-2 mRNA, as previously described [48]. 
Briefly, 5μm thick tissue sections were deparaf-
finized, rehydrated through graded alcohols to 
distilled water and permeabilized with 200μl of 
10μg/mL proteinase K for 5-20 minutes de-
pending on tissue type. The deproteination reac-
tion was stopped by washing slides two times, 
three minutes each in Nanopure ultrapure wa-
ter, followed by sequential washes in 95% and 
100% ethanol for three minutes each. Slides 
were allowed to air dry for one hour at room 
temperature (RT), prior to hybridization. Tissue 
sections were then incubated in a humidified 
chamber overnight (12-14 hours) at 37ºC with 
50μL of PRL-1, PRL-2, or control probe diluted 
to a final concentration of 750 ng/mL in Perfec-
tHyb™ Plus hybridization buffer (Sigma-Aldrich, 
St. Louis, MO, USA). Following hybridization, non
PRL-1 and PRL-2 expression in cancer 
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-specifically bound probe was removed by wash-
ing slides two times in 2X SSC (300mM NaCl, 
30mM Sodium Citrate, pH 7.0) plus 0.1% SDS 
for five minutes RT, one time in pre-warmed 
0.5X SSC (75mM NaCl, 7.5mM Sodium Citrate, 
pH 7.0) + 0.1% SDS at 37ºC for 20 minutes, 
and one time in tris-buffered saline (TBS; 50mM 
Tris-HCL, 150mM NaCl, pH 7.6) + 0.1% SDS at 
RT for 10 minutes. Detection of hybridized 
probe was performed by standard immunohisto-
chemical techniques using a catalyzed signal 
amplification procedure. Non-specific back-
ground staining was blocked by incubation with 
DAKO Serum-Free Protein Block (DAKO Corpora-
tion, Carpenteria, CA, USA) for 30 minutes, fol-
lowed by 30 minutes incubation with a mouse 
anti-FITC primary antibody (DAKO), diluted to 
22μg/mL in DAKO Antibody Diluent. Bound pri-
mary antibody was detected using the labeled 
streptavidin-biotin method (LSAB2, DAKO) com-
bined with the Renaissance® Tyramide Signal 
Amplification kit (TSA™ Biotin, PerkinElmer Life 
Sciences, Inc., Boston, MA, USA). Peroxidase 
bound, antibody complexes were visualized us-
ing DAB (DAB Substrate/Chromogen System, 
DAKO) as the chromogenic substrate. Develop-
ment was allowed to proceed for 2-5 minutes 
and was stopped by rinsing the slides in distilled 
water for five minutes. Sections were counter-
stained briefly with 1X Lerner’s hematoxylin, 
dehydrated through graded alcohols, cleared in 
xylene, and coverslipped with permanent 
mounting media (ThermoFisher Scientific, Inc., 
Waltham, MA, USA). All staining steps were per-
formed on a DAKO Autostainer at room tem-
perature and slides were rinsed for five minutes 
in TBS + 0.05% Tween-20 between each step of 
the procedure. Normal adjacent and tumor tis-
sue sections from one organ type were always 
processed simultaneously.  
 
Immunohistochemistry 
 
Rabbit antibodies against peptides correspond-
ing to amino acids 50-65 of human PRL-1 and 
47-62 of human PRL-2 were generated by 
Genemed Synthesis, Inc (San Antonio, TX, USA). 
The antibodies were affinity purified against E. 
coli expressed PRL proteins. Slides containing 
5μm tissue sections were deparaffinized for 9 
minutes in xylene then rehydrated through a 
series of 100%, 80%, and 70% ethanol for 5 
minutes each, followed by a 5 minute rinse in 
PBS. Antigen retrieval was performed by heating 
in a microwave for 5 minutes in 5mM Sodium 
Citrate. Following retrieval, slides were allowed 
to cool at room temperature for 15 minutes. 
Endogenous peroxidase activity was quenched 
by incubation in 3% H2O2 for 5 minutes. Sec-
tions were blocked for 15 minutes in 3% non-fat 
dry milk, 1% BSA, then incubated 90 minutes at 
37°C with primary antibody diluted 1:200 in 
blocking solution. This was followed by a 30 
minute incubation with biotinylated secondary, 
anti-rabbit antibody (Biogenex Laboratories, 
Inc., Fremont, CA, USA) diluted 1:20 in blocking 
buffer and a 30 minute incubation with strepta-
vidin peroxidase (Biogenex). A 5 minute phos-
phate buffered saline (PBS) rinse was incorpo-
rated after each step in the immunostaining 
procedure. Colorimetric detection was carried 
out using AEC and allowed to proceed until color 
was detected in the tissues by microscopic ex-
amination at which point the reaction was 
quenched by rinsing the slides in distilled water. 
Sections were counterstained in Hematoxylin for 
30 seconds and again rinsed with water.  
 
Controls 
 
Several positive and negative controls were 
used, concurrently, to confirm the specificity of 
the ISH or IHC signal. All controls were per-
formed on serial sections of the same tissues 
as examined with the PRL-1 and PRL-2 probes 
or antibodies, utilizing the ISH and IHC proce-
dures described above. For the ISH experi-
ments, positive controls included: (a) verifica-
tion of the hybridization and detection proce-
dure by hybridization of the PRL-1 and PRL-2 
antisense probes to a normal pancreas tissue 
(case # 032098), known to be positive for PRL-
1 and PRL-2 mRNA and (b) hybridization of tis-
sues with a fluorescein-conjugated Poly d(T) 
probe (Novocastra Laboratories, New Castle 
upon Tyne, UK) to assess the preservation and 
integrity of the mRNA in each sample. Negative 
controls consisted of: (a) omission of the oli-
gonucleotide probes from the hybridization mix-
ture and incubation of the tissue specimens 
with only PerfectHyb™ hybridization buffer, (b) 
substitution of the specific antisense probe with 
an equivalent concentration of labeled sense 
probe to examine the stringency of the assay, 
(c) hybridization using a cocktail of randomly 
generated, FITC-conjugated, oligonucleotide 
sequences (NCL-CONTROL, Novocastra), to as-
sess binding of nonspecific sequences, and (d) 
Pretreatment of tissue sections with 250μg/mL 
RNase A (Sigma-Aldrich) for 2 hours at 37ºC to 
PRL-1 and PRL-2 expression in cancer 
 
 
86                                                                                                                Am J Transl Res 2012;4(1):83-101 
demonstrate the specificity of the signal for sin-
gle stranded RNA. Probe specificity was also 
verified by slot-blotting and shown previously 
[48]. As negative controls for IHC, tissue sec-
tions were incubated either in the presence of 
no primary antibody, no secondary antibody, or 
primary antibody blocked with the peptide used 
to generate the anti-PRL-1 or anti-PRL-2.  
 
Staining interpretation 
 
Evaluation of all slides was performed under 
bright-field microscopy. The intensity of staining 
and the percentage of positive normal and tu-
mor cells for the ISH studies were evaluated 
with the aid of a single, experienced pathologist, 
in a blinded fashion. For the IHC experiments, 
scoring of images was performed independently 
by three separate individuals and the mean 
reading was taken for each tissue section. The 
appearance of a brownish-red stain over the 
cells was used to indicate probe hybridization or 
antibody binding and thus reflect the cellular 
levels of PRL-1 and PRL-2 mRNA or protein. Im-
munostaining was scored using established 
methods [49, 50]. Briefly, staining intensity was 
classified according to the following scale: (-) 
absent, (+/-) barely detectable, (+) weak, (++) 
moderate, and (+++) strong. In cases of hetero-
geneous staining, the average intensity across 
the tissue was taken as the score. Also, in a few 
cases where a patient sample was stained 
twice, the case was given a mean score, based 
on evaluation of the two sections. The percent-
age of positive cells was estimated as the num-
ber of stained cells, per total number of cells 
counted. The localization of staining within the 
cells of each tissue was also examined and 
noted as nuclear, cytoplasmic, membranous, or 
a combination of these. For semiquantitative 
analysis of the results, the staining intensity was 
assigned an arbitrary value, on a scale of 0-3, 
as follows: (-) = 0, (+/-) = 0.5, (+) =1, (++) = 2, 
(+++) = 3. An overall staining score (SS) was 
calculated for each sample, by multiplying the 
staining intensity times the percentage of posi-
tive cells. After multiplication of both values, 
results were graded from 0 (negative) to 300 
(all cells display strong staining intensity). To 
confirm the reproducibility of the analysis, 25% 
of the slides were randomly chosen and scored 
twice. Duplicate readings gave similar results. 
Images were acquired using a SPOT digital cam-
era and imaging software (Diagnostic Instru-
ments, Inc., Sterling Heights, MI, USA).  
Statistical analysis 
 
Statistical calculations were executed using 
Statistical Analysis System software (SAS ver-
sion 8.2, SAS Institute, Inc., Cary, NC). Analyses 
of differences in PRL expression between can-
cerous and noncancerous tissues were per-
formed using a Student’s paired t-test. Results 
are expressed as mean ± standard error of the 
mean (SEM) and P < 0.05 was considered sta-
tistically significant. For most samples, the 
medical histories of the patients and pathologi-
cal reports for each specimen were also avail-
able. These were reviewed and correlations be-
tween PRL expression and patient clinicopa-
thological features such as patient age and gen-
der; tumor type, subtype, and grade; and pres-
ence of local or distant metastasis were calcu-
lated using a mixed model analysis of variance. 
Again, P < 0.05 was deemed statistically signifi-
cant. 
 
Results 
 
PRL-1 and PRL-2 transcripts are expressed in a 
broad variety of normal and tumor tissues 
 
A total of 285 normal, benign, and malignant 
human tissue samples of diverse origin were 
obtained from archival paraffin blocks and sub-
jected to ISH, in order to examine expression of 
PRL-1 and PRL-2 mRNA transcripts (Table 1). 
PRL-2 message was found to be expressed at 
moderate to high levels in almost all (279/285) 
of the normal and tumor tissues examined. Low 
levels of PRL-2 were noted only in a single case 
of renal cell carcinoma, one normal lymph node, 
one ovarian carcinoma, and three normal speci-
mens from the spleen. PRL-1 mRNA was also 
expressed in the vast majority of tissues exam-
ined, however the degree and intensity of PRL-1 
staining varied considerably between tissue 
types and between individual cases within a 
single tissue type. This transcript was expressed 
at detectable levels in 97% (133/137) of his-
tologically normal tissues examined, as well as 
in 93% (14/15) of breast carcinomas, 83% 
(5/6) of endometrial adenocarcinomas, 78% 
(14/18) of ovarian tumors, 77% (10/13) of re-
nal cell carcinomas, and in 100% of primary 
tumors derived from the bladder (n=9), cervix (n 
= 1), colon (n = 5), liver (n = 4), lung (n = 8), 
pancreas (n = 14), prostate (n = 28), skin (n = 
1), stomach (n = 5), and testis (n = 4). PRL-1 
was also expressed in all cases examined of B-
PRL-1 and PRL-2 expression in cancer 
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 Table 1. Expression of PRL-1 and PRL-2 in various tumors and diseased tissues 
Tissue Type/Histopathology # Samples 
PRL-1   PRL-2 
Weak 
(%) 
Moderate 
(%) 
Strong 
(%)   
Weak 
(%) 
Moderate 
(%) 
Strong 
(%) 
Bladder                 
   Transitional Cell Carcinoma 7 0 71 29   0 0 100 
   Sarcomatoid Carcinoma 1 100 0 0   0 0 100 
   Undifferentiated Carcinoma 1 100 0 0   0 0 100 
   Hyperplastic Lesion 1 100 0 0   0 0 100 
Brain                 
   Alzheimer's 4 25 75 0   25 0 75 
   Multiple Sclerosis 2 0 0 0   100 0 0 
Breast                 
   Invasive Ductal Carcinoma 15 13 40 40   0 7 93 
   Benign Lesions 2 0 100 0   0 0 100 
Cervix                 
   Squamous Cell (LCK) 1 0 100 0   0 0 100 
Colon                 
   Adenocarcinoma 5 20 40 40   0 0 100 
   Metastatic Lesions in Liver 3 0 33 67   0 0 100 
   Crohn's Disease 2 0 0 100   0 0 100 
Coronary Arteries                 
   30-60% Occlusion 3 33 0 0   0 33 33 
   60-90% Occlusion 2 0 0 0   0 50 0 
Heart                 
   Heart Disease 7 43 0 0   14 86 0 
Kidney                 
   Renal Cell Carcinoma 13 38 31 8   8 8 84 
Liver                 
   Hepatocellular Carcinoma 4 0 100 0   0 0 100 
   Hepatitis 2 100 0 0   0 50 50 
   Steatosis 2 50 50 0   0 50 50 
Lung                 
  Non Small Cell Lung Cancer 8 0 37 63   0 12 88 
Lymph Node                 
   B-Cell Lymphoma 4 0 0 100   0 0 100 
   Hodgkin Lymphoma 1 0 0 100   0 0 100 
   Metastatic Lymphoma in Testes 1 0 0 100   0 0 100 
Ovary                 
   Epithelial Tumor 17 41 35 0   6 12 82 
   Dysgerminoma 1 0 100 0   0 0 100 
Pancreas                 
   Exocrine Tumor 12 0 8 92   0 0 100 
   Endocrine Tumor 2 0 0 100   0 0 100 
   Diabetic 8 0 0 100   0 0 100 
Prostate                 
   Adenocarcinoma 28 25 25 50   0 0 100 
Skeletal Muscle                 
   Diabetic 4 0 50 0   0 25 75 
Skin                 
   Basal Cell Carcinoma 1 100 0 0   0 0 100 
Spleen                 
   Chronic Lymphocytic Leukemia 1 100 0 0   0 100 0 
   Chronic Myelogenous Leukemia 1 0 0 100   0 0 100 
   Diabetic 3 0 67 0   0 33 67 
Stomach                 
   Adenocarcinoma 4 0 0 100   0 0 100 
   Leiomyosarcoma 1 0 0 100   0 0 100 
Testis                 
     Germ Cell Tumor 4 0 50 50   0 0 100 
Uterus                 
   Adenocarcinoma 6 33 50 0   0 17 83 
   Sarcoma (MMMT) 1 0 0 100   0 0 100 
Vasculature (Multi Tumor Tissues) 38 21 32 45   0 5 95 
Stroma (Multi Tumor Tissues) 90 41 29 17   0 12 88 
Abbreviations: LCK = Large Cell Keratinizing; MMMT = Malignant Mixed Mullerian Tumor 
PRL-1 and PRL-2 expression in cancer 
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cell lymphoma (n = 5, including one metastatic 
lesion in the testes), Hodgkin lymphoma (n = 1), 
chronic lymphocytic leukemia (CLL; n = 1), 
chronic myelogenous leukemia (CML; n = 1), 
colon metastases to the liver (n = 3), uterine 
sarcoma (n = 1), and benign lesions of the 
breast (n = 2). In the vast majority of cases 
(both normal and tumor), localization of PRL-1 
and PRL-2 staining appeared to be nuclear, 
however in tissues of the breast, liver, pancreas, 
stomach, and uterus, both nuclear and cytoplas-
mic staining were observed. 
 
Dysregulation of PRL-1 and PRL-2 mRNA ex-
pression in tumors is highly tissue specific 
 
To provide further insight into the role of the 
PRL genes in cancer development, PRL-1 and 
PRL-2 mRNA expression were directly compared 
between the tumor and normal tissues exam-
ined by ISH. In both the normal and tumor tis-
sues, a large degree of inter-individual variability 
was observed, particularly in PRL-1 expression, 
suggesting that comparisons between normal 
and diseased tissue from different patients 
could be misleading. To account for this, only 
case matched tumor and normal adjacent tis-
sue (NAT) specimens from the same patient 
were utilized in this analysis. Of the tissues ex-
amined, there were 94 cases where both tumor 
and normal samples were available (188 total 
tissue specimens). These included case 
matched specimens from the bladder (n = 5), 
breast (n = 15), colon (n = 5), kidney (n = 13), 
liver (n = 4), lung (n = 8), ovary (n = 6), pan-
creas (n = 10), prostate (n = 13), spleen (n = 1), 
stomach (n = 5), testis (n = 4), and uterus (n = 
5). 
 
Direct comparison between normal and tumor 
samples revealed several significant, yet highly 
tissue specific differences in PRL-1 and PRL-2 
mRNA expression (Figures 1 and 2). PRL-1 ex-
pression was significantly higher in 100% of the 
gastric carcinomas examined as compared to 
adjacent normal gastric tissue, with an almost 2
-fold higher mean staining score in the cancer-
ous tissue than in the noncancerous tissue (P = 
0.01, Stomach, Figures 1 and 3). PRL-1 was 
also significantly overexpressed in 100% of 
hepatocellular carcinomas (HCC) compared to 
the matched normal tissues examined (P = 
0.0052) with 4-fold higher expression occurring 
in the tumor tissues in this instance. PRL-2 mes-
sage was also found to be upregulated in 100% 
of the hepatocellular carcinomas examined (P = 
0.0152, Liver, Figure 1) with levels of PRL-2 
expression in the HCC tissues, on average, ap-
proximately 2-fold higher than in normal hepato-
cytes (P = 0.0152). 
 
Given the evidence for a role of the PRL en-
Figure 1. Levels of PRL-1 transcript in matched tumor and adjacent normal tissue pairs. The mean staining scores 
(SS) ± the SEM are shown. An asterisk indicates a statistically significant difference between the matched normal 
versus tumor tissue, as determined by paired t-tests (P < 0.05). A statistically significant increase in PRL-1 mRNA 
expression was found in hepatocellular carcinomas (P = 0.0052, n = 4), and carcinomas of the stomach (P = 0.01, n 
= 5), compared to matched normal tissues. A significant decrease in PRL-1 mRNA expression was found in breast 
tumor tissue (P = 0.0058, n = 15), lung tumors (P = 0.015, n = 8), and ovarian carcinomas (P = 0.0007, n = 6) com-
pared to matched normal tissues. 
PRL-1 and PRL-2 expression in cancer 
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zymes in tumor development and metastasis, it 
was not surprising to find PRL-1 and PRL-2 ex-
pression increased in a variety of tumor tissues. 
Unexpectedly however, expression of both 
genes was also found to be lower, relative to the 
normal adjacent tissues, in a number of tumor 
types. PRL-1 transcript levels were significantly 
decreased in 100% of ovarian carcinomas (P = 
0.0007, Ovary, Figure 1), twelve (80%) of 15 
benign and malignant breast tumors (P = 
0.0058, Figures 1 and 4), and 6 (75%) of 8 lung 
carcinomas (P = 0.0148) with respect to the 
paired normal tissues for each. A similar down-
ward trend appeared to occur for 80% of the 
colon carcinomas, 69% of the renal cell carcino-
mas, 80% of the testicular carcinomas, and 
80% of the uterine carcinomas examined, how-
ever the differences in these tissues did not 
reach statistical significance. For PRL-2, seven 
(54%) out of 13 renal cell carcinomas showed a 
Figure 2. Levels of PRL-2 transcript in matched tumor and adjacent normal tissue pairs. The mean staining scores 
(SS) ± the SEM are shown. An asterisk indicates a statistically significant difference between the matched normal 
versus tumor tissue, as determined by paired t-tests (P < 0.05). Only hepatocellular carcinomas exhibited a statisti-
cally significant difference, with an approximately 2-fold increase in PRL-2 mRNA expression (P = 0.015, n = 4) in the 
tumors compared to normal liver tissue from the same subjects. 
Figure 3. Increased levels of PRL-1 mRNA in carcinomas of the stomach. A representative example shows that PRL-1 
message is expressed at significantly higher levels in a gastric adenocarcinoma (A) than in the normal gastric tissue 
from the same individual (B). Counterstained with hematoxylin. Magnification x 400. 
PRL-1 and PRL-2 expression in cancer 
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slight decrease in PRL-2 expression compared 
to the matched normal tissues (P = 0.049). 
Likewise, 38% of lung carcinomas, 40% of ovar-
ian and 60% of uterine carcinomas showed a 
small decrease in PRL-2 mRNA levels compared 
to corresponding normal tissues, but these 
changes were not found to be statistically sig-
nificant. Both PRL-1 and PRL-2 were also down-
regulated almost 2-fold in a single case of 
chronic lymphocytic leukemia compared to nor-
mal splenic B cells from the same patient, but, 
with only one tumor and matched normal sam-
ple in this case, statistical comparisons for this 
tumor type could not be made. No significant 
changes or trends in either PRL-1 or PRL-2 were 
observed in the overall mRNA expression be-
tween bladder, pancreatic, or prostate tumors 
and their respective matched normal adjacent 
tissues. 
 
PRL-1 and PRL-2 mRNA expression in tumor 
stroma and vasculature 
 
In addition to analyzing PRL-1 and PRL-2 ex-
pression patterns in multiple tumors and their 
normal cellular counterparts, expression of 
these transcripts was also compared between 
the stroma and vasculature of each subject’s 
tumor (Table 1) and normal tissue. PRL-1 mes-
sage was expressed in the vasculature of 100% 
of the normal tissues and 98% of the tumor 
tissues examined, with highly variable degree 
Figure 4. Decreased levels of PRL-1 mRNA in benign and malignant tumors of the breast. PRL-1 mRNA expression in 
(A) normal breast tissue and (B) a case matched, invasive ductal carcinoma of the breast. Counterstained with hema-
toxylin. Magnification x200. (C) Semi-quantitative analysis of PRL-1 mRNA expression in breast tumors (n = 15) and 
their matched normal adjacent tissues (n = 15). Horizontal lines represent the mean values for each group. Differ-
ences between the groups were found to be statistically significant by paired t-test (P = 0.0058). (D) PRL-1 mRNA 
expression in individual cases of matched tumor and adjacent normal tissue of the breast, showing a decrease in 
PRL-1 mRNA transcripts in 12/15 (80%) tumor tissues compared to their matched normal counterparts. Vertical lines 
connect matched tissue pairs from the same patient. 
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and intensity of staining. Only one specimen, a 
uterine adenocarcinoma, did not display PRL-1 
staining in the tumor vasculature, although very 
low levels of PRL-1 message were detectable in 
the glandular tissue of this tumor. In the stroma, 
PRL-1 was expressed in 95% of both the normal 
and tumor tissue sections examined, again with 
highly variable levels of expression from tissue 
to tissue. In most of the cases where an ab-
sence of PRL-1 staining was observed in the 
stroma, staining of all other structures within 
the tissue was also weak to absent. However, in 
2/4 normal breast tissues where PRL-1 mRNA 
expression was not detected in the stroma, PRL-
1 was expressed at moderate to high levels in 
the ductal epithelium. Likewise, in one 
squamous cell carcinoma of the lung which 
lacked PRL-1 expression in the stroma, PRL-1 
was expressed at moderate levels in the tumor 
epithelium. PRL-2 was expressed at moderate 
to high levels in the vasculature and stroma of 
all 190 cases examined. 
 
Similar to its upregulation in adenocarcinomas 
of the stomach, PRL-1 was also overexpressed 
in the stroma of each stomach tumor tissue 
examined (Figure 3), compared to the stroma of 
the corresponding normal adjacent tissues (P = 
0.0382). In the bladder, although no clear dif-
ferences in PRL expression existed between the 
normal and malignant urothelial cells, a signifi-
cant decrease in PRL-1 expression was ob-
served in both the bladder tumor vasculature (P 
= 0.0199) and the stroma surrounding the tu-
mor (P = 0.0182), as compared to these struc-
tures in the normal adjacent tissue samples. 
PRL-2 expression was also significantly de-
creased in the stroma of bladder carcinomas (P 
< 0.0001). Unlike PRL-1, PRL-2 expression was 
not significantly altered in the bladder tumor 
vasculature and displayed high levels of expres-
sion in all normal and tumor tissues. Levels of 
PRL-1 and PRL-2 message in the stroma and 
vasculature were not significantly different be-
tween the normal and tumor tissue pairs of any 
other tissue type. 
 
Expression of PRL-1 and PRL-2 transcripts in 
other human diseases 
 
In addition to carcinogenesis, protein tyrosine 
phosphatases have also been implicated in sus-
ceptibility to, or progression of, various other 
diseases, such as inflammatory and autoim-
mune diseases, neurodegenerative diseases, 
and cardiovascular disease. The PRL family 
member PRL-3 itself has been linked to a role in 
heart disease [5]. Therefore, in an attempt to 
analyze the relationship between PRL expres-
sion and various other disease states, PRL-1 
and PRL-2 mRNA expression were examined in 
the affected organs from patients with Alz-
heimer’s disease (n = 4), multiple sclerosis (n = 
2), crohn’s disease (n = 2), heart disease (n = 
7), coronary artery disease (n = 5), hepatitis (n = 
2), liver steatosis (n = 2), insulin-dependent 
diabetes mellitus (n = 6), and noninsulin-
dependent diabetes (n = 2). A student’s t-test 
was used to compare the mean staining scores 
between each set of diseased tissues and a set 
of histologically normal samples of the same 
tissue type, from different subjects.  
 
PRL-1 expression was again highly variable in all 
tissue types examined. PRL-2 message was 
expressed at moderate to high levels in all tis-
sues examined, with the exception of the brain 
and heart where, like PRL-1, its expression was 
quite variable (Table 1). In the small sample set 
analyzed here, no significant correlations were 
found between either PRL-1 or PRL-2 gene ex-
pression and any of the disease states exam-
ined. There did appear to be a trend toward in-
creased expression of PRL-1 in the brains of 
Alzheimer’s disease patients, where 75% of 
subjects had a SS > 150 in sections from the 
cerebral cortex and hippocampus, while 60% of 
normal subjects displayed SS < 50 in the same 
regions. However, considering the correlations 
with patient age discussed below, this trend is 
unlikely to be significant.  
 
Correlation between PRL-1 and PRL-2 mRNA 
expression and patient clinicopathological pa-
rameters 
 
To evaluate the clinical relevance of PRL-1 and 
PRL-2 expression in each tissue type examined, 
where possible (sufficient sample size and avail-
able patient data), a mixed model analysis of 
variance was used to analyze the relationship 
between the PRL staining scores and several 
clinicopathological features, including patient 
age, patient gender, tumor type, tumor subtype, 
tumor grade, and evidence of tumor metastasis 
(Tables 1 and 2). The intensity of PRL staining 
was also compared to the localization of the 
staining (whether nuclear, cytoplasmic, mem-
branous, or a combination of these) to examine 
any correlations between the two and the stain-
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Table 2. Patient and sample characteristics 
 
Tissue Type 
Total Number Gender Age (years) Tumor Grade Metastasis 
Samples Subjects Tumors M F Unk Mean Range High Intermediate Low Unk Y N Unk 
Bladder 16 10 9 4 6 0 71 60-81 6 3 0 0 1 8 0 
Brain 16 11 0 7 4 0 68 50-87 0 0 0 0 0 0 0 
Breast 35 20 17 0 20 0 58 38-85 12 4 1 0 7 6 4 
Cervix 6 6 1 0 6 0 40 30-44 0 1 0 0 0 1 0 
Colon 16 11 8 7 3 1 69 29-94 2 4 2 0 7 1 0 
Coronary Artery 5 5 0 4 1 0 57 37-78 0 0 0 0 0 0 0 
Heart 11 11 0 7 4 0 45 9-73 0 0 0 0 0 0 0 
Kidney 26 13 13 8 5 0 64 8-81 3 9 1 0 4 9 0 
Liver 16 12 4 5 7 0 54 1-75 0 0 4 0 0 0 4 
Lung 16 8 8 6 2 0 66 57-76 6 2 0 0 5 3 0 
Lymph Node 11 11 5 7 4 0 44 7-82 3 0 2 0 1 0 4 
Ovary 29 24 18 0 24 0 47 17-74 9 6 3 0 4 2 12 
Pancreas 38 28 14 10 9 9 47 3-79 8 5 0 1 6 0 8 
Prostate 41 28 28 28 0 0 63 51-75 14 10 4 0 2 3 23 
Skeletal Muscle 9 9 0 5 3 1 55 16-90 0 0 0 0 0 0 0 
Skin 4 4 1 1 1 2 52 51-52 0 0 1 0 0 1 0 
Spleen 12 11 2 8 3 0 41 13-71 0 0 1 1 0 0 2 
Stomach 10 5 5 4 1 0 72 46-85 4 1 0 0 4 0 1 
Testis 10 5 4 5 0 0 45 28-82 2 1 1 0 0 1 3 
Uterus 16 11 7 0 11 0 47 20-68 2 5 0 0 1 1 5 
Abbreviations: M = male; F = Female; Unk = Unknown; Y = Yes; N = No 
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ing localization was also individually compared 
to each of the various clinicopathological pa-
rameters. 
 
Levels of PRL-1 expression were found to be 
correlated with patient gender in neoplasms of 
the bladder (P = 0.006), where the male sub-
jects all exhibited significantly higher PRL levels 
than the female subjects (Figure 5). Expression 
levels of PRL-1 were also correlated with age in 
some tissue types. PRL-1 staining scores signifi-
cantly decreased with patient age in the skeletal 
muscle (P = 0.0031, Figure 6A) with very low 
expression levels attained after ages greater 
than 75 years. In contrast, PRL-1 strongly in-
creased with patient age in the brain (P = 
0.0252, Figure 6B) with sharp increases ob-
served in patients over the age of 60 years. In 
several tumor tissues, expression of PRL-1 and -
2 was significantly correlated with increasing 
tumor grade (increasing severity). In the ovary 
(Figure 7A), well-differentiated tumors ex-
pressed little to no PRL-1, while the less organ-
ized moderately-differentiated and poorly differ-
entiated tumors tended to express higher levels 
of the transcript (P = <0.0001). There were no 
well-differentiated carcinomas of the uterus in 
this study, however the poorly differentiated 
carcinomas expressed PRL-1 to a significantly 
higher degree than the moderately differenti-
ated uterine tumors (P = 0.0441). In the pros-
tate (Figure 7B), mean PRL-1 staining scores 
once more increased from the low grade, more 
differentiated tumors (Gleason grades 1-4) to 
the moderate grade tumors (Grades 5-7). How-
ever, the mean staining score again decreased 
in the more poorly differentiated, high grade 
(Grades 8-10) prostate tumors (P = 0.0126). In 
the testes, little to no PRL-2 expression was 
Figure 5. Gender specific expression of PRL-1 in the 
bladder. Semi-quantitative analysis of PRL-1 mRNA 
expression in male (n = 4) and female (n = 6) bladder 
tissues. Horizontal lines represent the mean values 
for each group. Differences between the two groups 
were found to be statistically significant by paired t-
test (P = 0.006). 
Figure 6. PRL-1 levels correlate with age in the skele-
tal muscle and brain. Semi-quantitative analysis 
showed that PRL-1 mRNA expression is negatively 
correlated with patient age in the skeletal muscle (A) 
and positively correlated with patient age in the brain 
(B). In both cases, mixed model analysis found the 
results to be statistically significant (P < 0.05). Brain 
specimens included tissue sections from the cere-
brum, hippocampus, substantia nigra, and cerebel-
lum. Different regions of the brain within the same 
individual displayed similar staining scores. The aver-
ages of these are represented. 
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observed in a well-differentiated germ cell tu-
mor, but high levels of PRL-2 were noted in both 
the moderately and poorly differentiated tu-
mors. In this tissue type, however, the number 
of samples in each category was too small to 
make any statistical comparisons. No clear as-
sociations were found between the intensity of 
PRL-1 or PRL-2 staining and the localization of 
the staining, nor between the localization of 
staining and any of the clinicopathological pa-
rameters examined. There were also no correla-
tions found, in this data set, between PRL-1 or -
2 expression and histologic subtype (e.g. clear 
cell vs. chromophobe cell type renal cell carcino-
mas of the kidney; adenocarcinoma vs. 
squamous cell non-small cell cancer of the lung, 
etc.) or with the presence or absence of local or 
distant metastases in any tumor type.  
 
Correlation of PRL mRNA and protein expres-
sion 
 
To examine the relationship between PRL-1 and 
PRL-2 expression at the mRNA and protein lev-
els, select cases from various tissue types and 
representing a wide range of expression levels 
via ISH (RNA) were also examined by IHC 
(protein). The degree of expression for each was 
scored, in a blinded fashion, by different indi-
viduals than those who scored the ISH results 
and the general levels of expression (high, me-
dium, or low) for the mRNA and protein were 
then compared. Using this approach it is not 
possible to compare absolute levels of RNA and 
protein, however, the relative changes seen in 
comparing various tissues and in comparing 
tumor and normal adjacent tissue can be use-
ful. In the majority of the 30 individual cases 
examined, PRL-1 mRNA and protein were ex-
pressed at similar relative levels (Figure 8A). In 
cases where the relative levels differed, staining 
was always more intense for PRL-1 mRNA than 
for the protein. In half of the same 30 tissue 
sections, PRL-2 mRNA staining intensity was 
also higher than that for PRL-2 protein (Figure 
8B). In the remaining half of cases, PRL-2 mRNA 
and protein appeared to be expressed at similar 
levels (37%) or the staining intensity for the pro-
tein was higher than that for the mRNA (13%).  
 
Within the 30 tissues probed by both ISH and 
IHC, there were 10 cases of paired tumor and 
normal adjacent tissue. Examination of these 
tissue pairs revealed that 6 of 10 cases for PRL-
1 (concordance = 60%) and 8 of 10 cases for 
PRL-2 (concordance = 80%) displayed the same 
Figure 7. Correlation of PRL-1 expression with tumor grade in the ovary and prostate. (A) Expression levels, in arbi-
trary units, of PRL-1 mRNA in human ovarian carcinomas (n = 18) of varying histologic grade. WD = well-
differentiated; MD = moderately differentiated; PD = poorly differentiated. (B) Expression levels, in arbitrary units, of 
PRL-1 mRNA in human prostate carcinomas (n = 28) of varying histologic grade. Horizontal lines represent the mean 
values for each group. In both tissue types, mixed model analysis found the results to be statistically significant (P < 
0.05). 
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trends of expression between the RNA and pro-
tein (e.g. both increased from the normal adja-
cent to the tumor tissue; both decreased from 
the normal adjacent to the tumor tissue; or nei-
ther changed). This suggested that there was 
good overall concordance between the RNA and 
protein results and that, in general, changes 
occurring at the mRNA level here are reflective 
of those occurring at the protein level. 
 
Discussion 
 
Accumulating evidence has implicated the PRL 
family of phosphatases as having an oncogenic 
role in human cancers [1, 4-7]. For example, it 
is now well known that PRL-3 expression is gen-
erally absent from normal adult human tissues, 
but frequently elevated in a variety of benign 
and malignant human neoplasms, where it may 
serve as a marker for tumor aggressiveness, 
increased tumor angiogenesis, and/or poor 
prognosis [9, 10, 12, 18, 21-27, 31, 35-37, 51]. 
Here, we used in situ hybridization to examine 
the expression of PRL-1 and PRL-2 in human 
malignancies with the aim of providing further 
insight into the role these two PRL family mem-
Figure 8. Comparison between mRNA and protein expression levels. PRL-1 (A) and PRL-2 (B) mRNA and protein ex-
pression levels were compared in a selection of 30 normal and tumor tissues from a variety of tissue types. Brackets 
indicate matched normal adjacent and tumor tissue pairs from the same individual. The plus sign in (A) denotes a 
sample for which no expression of PRL-1 protein was detected; however a small arbitrary value was assigned so that 
this sample would appear on the graph.  
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bers play in disease pathogenesis. 
 
PRL-1 and PRL-2 transcript levels were evalu-
ated across 285 normal, benign, and malignant 
tumor tissues, where both transcripts were 
found to be ubiquitously expressed. While PRL-2 
transcripts were consistently abundant across 
almost all specimens, PRL-1 expression was 
highly variable, not only between tissue types, 
but also from individual to individual within a 
given tissue type. Since such a high degree of 
patient-to-patient variability in PRL-1 expression 
could confound results when making compari-
sons between groups of unmatched normal and 
tumor tissues from different subjects, only 
matched tumor and normal adjacent tissue 
(NAT) samples taken from the same individuals 
were used to evaluate changes in PRL gene 
expression that might occur as a result of neo-
plastic transformation. Given current knowledge 
of the role that the PRL enzymes play in promot-
ing tumor development and progression, we 
hypothesized that PRL-1 and PRL-2 gene ex-
pression would each be upregulated in a num-
ber of tumor types relative to their matched nor-
mal tissue specimens. In accordance with this 
theory, PRL-1 and PRL-2 transcripts were each 
found to be significantly overexpressed in 100% 
of hepatocellular carcinomas (n = 4; p = 0.0052 
and 0.0152 respectively) and PRL-1 message 
was also significantly overexpressed in both the 
tumor (p = 0.01) and stroma (p = 0.0382) of 
100% of carcinomas from the stomach (n = 5). 
Increased levels of PRL-3 expression have previ-
ously been associated with the progression and 
metastasis of gastric and liver carcinomas [27, 
29-31, 34, 35, 39]. The current report is the 
first to suggest that PRL-1 and PRL-2 may also 
play an important role in the development and/
or progression of these tumor types. 
 
Surprisingly however, in other tissue types, a 
very different result was seen. In 100% of ovar-
ian (n=6; p = 0.0007), 80% of breast (n = 15; p 
= 0.0058), and 75% of lung (n = 8; p = 0.0148) 
tumors, PRL-1 levels were found to be signifi-
cantly lower in the neoplastic cells than in their 
matched, unaffected counterparts. Likewise, 
PRL-2 levels were significantly decreased in 
54% of carcinomas from the kidney (n = 13; p = 
0.049) relative to the matched normal controls. 
These results suggest that dysregulation of PRL-
1 and PRL-2 is a highly tissue specific event. 
This is consistent with observations of normal 
tissues, which have suggested that the PRL en-
zymes may be pleiotropic signaling molecules 
with a diversity of roles in different tissues and 
cell types [52, 53].  
 
In addition to a role in cancer, PTPs have been 
implicated in a growing number of human pa-
thologies, including cardiovascular, immunologi-
cal, infectious, neurological, and metabolic dis-
eases [44-47]. Therefore, we also sought to 
examine PRL-1 and PRL-2 mRNA expression in 
a small cohort of available samples from pa-
tients with various pathological conditions. In 
the panel of tissues examined here, PRL-1 and -
2 were widely expressed, however no significant 
correlations were found between PRL-1 or PRL-
2 expression levels and Alzheimer’s disease, 
multiple sclerosis, Crohn’s disease, coronary 
artery disease, heart disease, liver steatosis, 
hepatitis, or diabetes. 
 
To evaluate the extent to which deregulation of 
PRL expression might be related to known pa-
tient characteristics and clinicopathological vari-
ables, where possible, PRL-1 and -2 mRNA ex-
pression levels in each tissue type were corre-
lated to such features as patient age, patient 
gender, tumor histologic subtype, tumor grade, 
and presence/absence of tumor metastasis. In 
neoplasms of the bladder, expression levels of 
PRL-1 were found to be correlated to patient 
gender (p = 0.006), with male subjects display-
ing significantly higher PRL-1 transcript levels 
than female subjects. A similar trend toward 
increased expression in male subjects was also 
noted for PRL-2 in the lung (data not shown). 
Carter et al. [54] previously observed gender 
based differences of PRL-2 expression in rat 
brains, where PRL-2 mRNA was expressed at 3-
fold higher levels in the anterior pituitaries of 
male rats than in female rats. The current data 
thus support these prior observations that the 
PRL enzymes may play a sexually dimorphic role 
in select tissue types. Increased PRL-1 expres-
sion also correlated positively with patient age 
in the brain (p = 0.0252), yet negatively with 
patient age in the skeletal muscle (p = 0.0031). 
Advancing age of both the brain and skeletal 
muscle is associated with a decline in function 
as well as with several common accompanying 
changes in gene expression [55-57]. Interest-
ingly, in one transcriptional profiling study, 
aimed at identifying gene signatures for human 
aging in the frontal cortex [55], PRL-2 appeared 
on the list of genes which are significantly 
upregulated in the aging human brain. These 
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data suggest that both PRL-1 and PRL-2 may be 
putative players in, or be heavily influenced by, 
the aging process. Taken together, these results 
suggest that age and gender should be taken 
into account when evaluating sample to sample 
variations in PRL abundance and further under-
score the importance of using appropriately 
matched case controls in comparisons of PRL 
expression. 
 
PRL-1 or -2 mRNA levels were found to be asso-
ciated with tumor grade in some tissue types. 
Levels of PRL-1 in ovarian tumors increased 
significantly (p < 0.0001) in the moderate and 
poor grade tumors, relative to the low grade 
specimens, although this increase was to levels 
that remained appreciably lower than that seen 
in the NAT/normal specimens. A similar pattern 
of expression was observed for PRL-1 in the 
uterus and for PRL-2 in the testes. In the pros-
tate, a wide range of PRL-1 expression levels 
were observed across the histologically normal 
tissue specimens, as well as across cases of 
prostatic intraepithelial neoplasia (PIN) and be-
nign prostatic hyperplasia (BPH). However, in 
the prostate tumor specimens there was a sig-
nificant increase in PRL-1 expression going from 
the lower grade to the more moderate grade 
tumors (p = 0.0126), followed by a subsequent 
decrease in the higher grade tumors. These 
data suggest that alterations in PRL expression 
are an early event of carcinogenesis in many 
organ systems and that PRL-1 and/or PRL-2 
may serve as useful biomarkers for detection of 
tumorigenic lesions or for assessment of tumor 
aggressiveness in select tissue types. No corre-
lations were found between PRL-1 or -2 expres-
sion and any of the clinicopathological features 
examined in the breast, heart, kidney, liver, pan-
creas, spleen, or stomach. Nor was any associa-
tion seen between PRL expression and his-
tologic subtype or tumor metastasis in any of 
the tumor types examined. There were also no 
significant correlations between PRL-1 or PRL-2 
mRNA expression and clinical features related 
to colon cancer progression or metastasis, con-
sistent with a previous report examining PRL-1 
and PRL-2 protein in this tissue type [19].  
 
To determine whether changes seen at the RNA 
level are reflective of what is occurring in these 
tissues at the protein level, immunostaining 
results from anti-peptide, affinity-purified poly-
clonal antibodies specific to PRL-1 and PRL-2 
were directly compared to the ISH results in a 
subset of tissues from different tissue origin 
and demonstrating varied levels of PRL mRNA 
expression. Despite the presence of some varia-
tion between the absolute levels of PRL-1 or -2 
mRNA and protein in the analysis of individual 
cases, there was a clear correlation between 
the two with respect to the changes occurring 
during tumorigenesis. In comparisons of 
matched normal and tumor samples from the 
same patient, the mRNA and protein both exhib-
ited the same change (or conversely, lack of 
change) in expression 60% of the time for PRL-1 
and 80% of the time for PRL-2. When differ-
ences in the general expression levels (high, 
medium, low) between mRNA and protein oc-
curred, the mRNA was most often detected at 
higher levels than the protein. It is possible that, 
in each of these cases, changes occurring at the 
RNA level had not yet been reflected at the pro-
tein level. Alternatively, this could indicate post-
transcriptional control of these molecules, per-
haps through translational repression by PolyC-
RNA-binding protein 1 (PCBP1) or a similar 
molecule, as was recently described for PRL-3 
[58].  
 
Only a handful of studies have yet examined 
PRL-1 or PRL-2 expression in human malignan-
cies and even fewer have evaluated PRL-1 or 
PRL-2 in case matched normal and tumor sam-
ples. However, in general, the current results 
are in good agreement with previously pub-
lished reports. In the present study, PRL-1 and 
PRL-2 levels were consistently lower in primary 
tumors from the ovary, compared to paired nor-
mal tissues, suggesting that higher levels of PRL
-1 and -2 may be advantageous in this sample 
type. This is consistent with the observations of 
Reich et al. who showed that higher expression 
of PRL-1 or PRL-2 in ovarian cancer effusions 
correlated with better overall patient survival 
[59]. In contrast, the present data also show a 
relationship between increasing PRL-1 expres-
sion in ovarian carcinomas and advanced tumor 
grade. It is currently unclear how PRL-1 expres-
sion can be consistently downregulated in tu-
mor specimens and positively correlated with 
improved patient outcome, yet also show posi-
tive correlation to increased tumor aggressive-
ness. However, with respect to outcome, Reich 
et al. did not observe the same beneficial effect 
of PRL-1 and -2 on patient survival when the 
molecules were expressed in solid tumors. It is 
possible then that, in solid ovarian tumors, an 
initial knockdown of PRL-1 expression is re-
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quired for neoplastic transformation, following 
which enhanced levels of PRL-1 have no effect. 
Or PRL-1 could have an inhibitory effect on tu-
mor formation in the early stages of ovarian 
carcinogenesis, but play a tumor-promoting role 
in the latter stages. A similar dual, opposing role 
has previously been reported for other mole-
cules including Notch1 [60], MIC-1 [61], and for 
TGFβ [62], which has been shown to be an up-
stream regulator of PRL-3 [63]. In breast tissue, 
Hardy et al. [43] used real-time PCR to examine 
PRL-2 expression and found elevated levels of 
PRL-2 mRNA in primary breast tumors relative 
to matched normal tissue. The present data 
indicate a lack of change in PRL-2 expression 
between normal and neoplastic breast tissues, 
but PRL-2 levels in most breast tissues were 
extremely high and quite possibly at the limits of 
detection for the ISH system. In the pancreas, 
Stephens et al. [64] showed upregulation of 
PRL-1 and PRL-2 protein in 33% and 26% re-
spectively of pancreatic tumors in relation to 
matched NAT specimens. In the current study, 
similar results were noted for PRL-1 mRNA with 
increased expression of PRL-1 seen in 46% of 
pancreatic tumor specimens with respect to 
matched normal controls. However, in 36% of 
samples, the opposite effect was seen, with an 
increase of PRL-1 expression in the NAT tissue 
relative to tumor. And, in 18% of samples, no 
differences were seen between the two. In the 
current data for PRL-2, staining was always 
heavy and no detectable differences between 
PRL-2 expression in the tumor and NAT samples 
were observed.  
 
The results presented here show that, as with 
family member PRL-3, alterations in expression 
of PRL-1 and PRL-2 are a common event in hu-
man cancers; however, the nature of these al-
terations is highly tissue specific. In some tissue 
types, such as the stomach and liver, PRL-1 or -
2 expression associates with tumor promotion, 
whereas in other tissue types, like the ovary and 
lung, expression of these molecules may nor-
mally serve a protective function. The frequent 
deregulation of these molecules in human neo-
plasms suggests that they may be useful mark-
ers for cancer diagnosis. They may also serve as 
valuable therapeutic targets and/or indicators 
of increasing tumor severity in select tissue 
types. The mechanisms of PRL action and regu-
lation are currently poorly understood and the 
exact biological function of these molecules is 
unknown. Identifying the means by which their 
expression is regulated or the signaling path-
ways in which they act will be an important next 
step to provide insight into the pleiotropic role 
these molecules play in the carcinogenic proc-
ess. Characterization of the PRL signaling path-
ways may also enhance our understanding of 
the observed gender and age related variations 
in PRL-1 expression. The present results help to 
expand our current understanding of the differ-
ences that exist between PRL-1 and PRL-2 lev-
els in normal tissues and human malignancies 
and should facilitate larger scale retrospective 
or prospective studies examining the relevance 
of PRL-1 or PRL-2 in clinical cancer as well as in 
other human pathologies. 
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